Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Increase in Short Interest

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 799,400 shares, an increase of 22.9% from the November 30th total of 650,600 shares. Currently, 4.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 164,300 shares, the days-to-cover ratio is currently 4.9 days.

Institutional Trading of Telomir Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company's stock valued at $45,000 after purchasing an additional 5,367 shares during the last quarter. Beaird Harris Wealth Management LLC boosted its stake in Telomir Pharmaceuticals by 212.9% during the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company's stock valued at $70,000 after buying an additional 9,950 shares during the last quarter. State Street Corp grew its holdings in Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company's stock valued at $232,000 after buying an additional 17,967 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Telomir Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, Suncoast Equity Management increased its stake in Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock worth $329,000 after acquiring an additional 26,803 shares during the last quarter.

Telomir Pharmaceuticals Price Performance

Shares of TELO stock traded up $0.06 during mid-day trading on Friday, hitting $4.87. The company had a trading volume of 206,793 shares, compared to its average volume of 105,105. The stock's 50 day moving average price is $4.60 and its 200-day moving average price is $4.81. Telomir Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $20.72.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.